Skip to Content

Sesen Bio, Inc.

Merger

  • Date:
  • 9/21/2022
  • Company Name:
  • Sesen Bio, Inc.
  • Stock Symbol:
  • SESN
  • Company Name - Buyer:
  • Carisma Therapeutics Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 9/21/2022

Case Finder

Locate any case using the tools below.

NEW YORK, September 21, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Sesen Bio, Inc. (NASDAQ: SESN) (“Sesen Bio”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Carisma Therapeutics Inc. (“Carisma”).

On September 21, 2022, Sesen Bio announced that it had entered into an agreement to be acquired by Carisma in an all-stock deal. Pursuant to the merger agreement, pre-merger Sesen Bio stockholders are expected to own approximately 41.7% and pre-merger Carisma stockholders are expected to own approximately 58.3% of the combined company. The deal is expected to close in the next three to four months.

Bragar Eagel & Squire is concerned that Sesen Bio’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Sesen Bio’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Sesen Bio. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: